TYK2 and systemic lupus erythematosus: Several JAK inhibitors have been investigated in systemic lupus erythematosus, including baricitinib (JAK1/2 inhibitor), tofacitinib (JAK1/3 inhibitor), and the selective TYK2 inhibitor deucravacitinib.